• Product NameMLN8237(Alisertib)
• Brief DescriptionInhibitors
• Purification99.50%
• Biological ActivityAlisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM; has >200-fold higher selectivity for Aurora A than Aurora B.
• Target NameAurora Kinase inhibitor
• CAS No. 1028486-01-2
• Calculated MW 518.92
• Formulation C27H20ClFN4O4
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:COC1=C(C=CC(NC2=NC=C3CN=C(C4=C(C=CC(Cl)=C4)C3=N2)C2=C(OC)C=CC=C2F)=C1)C(O)=O
  Pathways:Cell Cycle/Checkpoint; Chromatin/Epigenetic
  Receptor:Aurora A; Aurora B
  Boling pt:729.134C
  Melting pt:
  Solubility:DMSO: 27 mg/mL (52.03 mM)
  Appearance:Yellow Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Sehdev V, et al. Mol Y Ther, 2012, 11(3), 763-774.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting